Dermata Therapeutics Inc

DRMA30 Nov 2024
Healthcare
$1.14
+0.03 (+2.57%)
Lowest Today
$1.1
Highest Today
$1.15
Today’s Open
$1.14
Prev. Close
$1.1
52 Week High
$13.35
52 Week Low
$1.05
To Invest in Dermata Therapeutics Inc

Dermata Therapeutics Inc

Healthcare
DRMA30 Nov 2024
+0.03 (+2.57%)
1M
3M
6M
1Y
5Y
Low
$1.1
Day’s Range
High
$1.15
1.1
52 Week Low
$1.05
52-Week Range
52 Week High
$13.35
1.05
1 Day
-
1 Week
-
1 month return
-16.66%
3 month return
-37.5%
6 month return
-70.27%
1 Year return
-90.12%
3 Years return
-99.83%
5 Years return
-
10 Years return
-
Institutional Holdings
Fidelity Extended Market Index
0.4
Tower Research Capital LLC
0.1
UBS Group AG
0.1
Fidelity Nasdaq Composite Index
0
Wells Fargo & Co
0
Bank of America Corp
0
State St US Extended Mkt Indx NL Cl C
0

Market Status

Fundamentals
Market Cap
2.24 mln
PB Ratio
0.47
PE Ratio
0
Enterprise Value
-3.9 mln
Total Assets
7.98 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Organisation
Dermata Therapeutics Inc
Employees
8
Industry
Biotechnology
CEO
Mr. Gerald T. Proehl
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step